Teva Pharmaceutical IndustriesFRA:TEV +2.68%60 PB Ratio is 5.01 as of Jul. 07, 2026, which is 236% above its 10-year median of 1.49. GuruFocus rates FRA:TEV with a GF Score™ of 60/100 and a GF Value™ of €17.78 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 81.43% on this metric.
Teva Pharmaceutical Industries Ltd stock PB Ratio (=5.01) is close to 1-year high of 5.28.
The historical rank and industry rank for Teva Pharmaceutical Industries's PB Ratio or its related term are showing as below:
FRA:TEV'
s PB Ratio Range Over the Past 10 Years
Min: 0.56 Med: 1.49 Max: 5.65
Current: 5.01
During the past 13 years, Teva Pharmaceutical Industries's highest PB Ratio was 5.65. The lowest was 0.56. And the median was 1.49.
FRA:TEV's PB Ratio is ranked worse than 81.43% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs FRA:TEV: 5.01
During the past 12 months, Teva Pharmaceutical Industries's average Book Value Per Share Growth Rate was 29.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -15.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Teva Pharmaceutical Industries was 47.20% per year. The lowest was -24.10% per year. And the median was 15.60% per year.
Back to Basics: PB Ratio
Teva Pharmaceutical Industries (FRA:TEV) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Teva Pharmaceutical Industries PB Ratio Related Terms
Teva Pharmaceutical Industries PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PB Ratio distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's PB Ratio falls into.
Teva Pharmaceutical Industries PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Teva Pharmaceutical Industries (FRA:TEV) has a PB Ratio of 5.01 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Teva Pharmaceutical Industries and its competitors. This is 236% above median its historical median of 1.49. Over the past decade, Teva Pharmaceutical Industries' PB Ratio has ranged from 0.56 to 5.65. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #750 out of 921 companies in the Drug Manufacturers industry, placing it in the top 81.4%.
Is Teva Pharmaceutical Industries' PB Ratio too high?
Teva Pharmaceutical Industries' current PB Ratio of 5.01 is 236% above median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 5.65. The Drug Manufacturers industry median PB Ratio is 1.93. Teva Pharmaceutical Industries' value of 5.01 is 159.6% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #750 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Teva Pharmaceutical Industries has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #750 out of 921 companies for PB Ratio. This places Teva Pharmaceutical Industries in the lower half of its industry. The industry median PB Ratio is 1.93. Teva Pharmaceutical Industries' value of 5.01 is 159.6% above this benchmark. Historically, Teva Pharmaceutical Industries' own PB Ratio has ranged from 0.56 to 5.65 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 1.93, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.93, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current PB Ratio of 5.01 is 159.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current PB Ratio is 5.01, which is 236% above median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.78, compared to a current price of €30.60 — trading 72.1% above its estimated fair value. The current PB Ratio is 5.01, which is 236% above median its 10-year median of 1.49 and 159.6% above the Drug Manufacturers industry median of 1.93. Teva Pharmaceutical Industries' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current PB Ratio is 5.01 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of €30.60 is trading 72.1% above its estimated GF Value™ of €17.78.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for FRA:TEV:
PB Ratio: 5.01 (236% above median its 10-year median of 1.49)
GF Value™: €17.78 vs. price of €30.60 (72.1% above fair value)
Industry Position: 159.6% above the Drug Manufacturers median (#750 of 921)
No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
60GF Score
Get the complete analysis for FRA:TEV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TEV has been successfully added to your 
